JPWO2006109367A1 - Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution - Google Patents

Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution Download PDF

Info

Publication number
JPWO2006109367A1
JPWO2006109367A1 JP2007512410A JP2007512410A JPWO2006109367A1 JP WO2006109367 A1 JPWO2006109367 A1 JP WO2006109367A1 JP 2007512410 A JP2007512410 A JP 2007512410A JP 2007512410 A JP2007512410 A JP 2007512410A JP WO2006109367 A1 JPWO2006109367 A1 JP WO2006109367A1
Authority
JP
Japan
Prior art keywords
cell
lactoferrin
solution
cells
fixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007512410A
Other languages
Japanese (ja)
Other versions
JP4724836B2 (en
Inventor
利明 石井
利明 石井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obihiro University of Agriculture and Veterinary Medicine NUC
Original Assignee
Obihiro University of Agriculture and Veterinary Medicine NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obihiro University of Agriculture and Veterinary Medicine NUC filed Critical Obihiro University of Agriculture and Veterinary Medicine NUC
Priority to JP2007512410A priority Critical patent/JP4724836B2/en
Publication of JPWO2006109367A1 publication Critical patent/JPWO2006109367A1/en
Application granted granted Critical
Publication of JP4724836B2 publication Critical patent/JP4724836B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

【課題】接着性動物細胞を浮遊状態で正常に培養増殖させ、この培養増殖させた接着性動物細胞を所望の場所に再び定着させる方法を提供する。【解決手段】本発明に係る細胞遊離法は、細胞を培養している培養器の培養液中にラクトフェリン(Lactoferrin)を加えることを特徴とするものである。また、本発明に係る細胞培養法は、ラクトフェリンを含む培養液中で細胞を浮遊培養することを特徴とするものである。また、本発明に係る細胞定着法は、ラクトフェリンを希釈するか、ラミニンを被覆した培養器に浮遊細胞を含む培養液を移すか、グリコサミノグリカンを添加することを特徴とするものである。これらにおいて、前記細胞は接着性動物細胞であり、前記培養液中には血清が含まれている。【選択図】図1An object of the present invention is to provide a method in which adherent animal cells are normally cultured and proliferated in a floating state, and the cultured and proliferated adherent animal cells are re-established in a desired place. A cell release method according to the present invention is characterized in that lactoferrin is added to a culture solution of a culture vessel in which cells are cultured. In addition, the cell culture method according to the present invention is characterized in that cells are suspended and cultured in a culture solution containing lactoferrin. The cell fixing method according to the present invention is characterized by diluting lactoferrin, transferring a culture solution containing floating cells to a laminin-coated incubator, or adding glycosaminoglycan. In these, the cells are adherent animal cells, and the culture medium contains serum. [Selection] Figure 1

Description

本発明は、ラクトフェリンを用いた細胞遊離法、細胞遊離液、細胞培養法、細胞培養液、細胞液、細胞液製剤、細胞定着法及び細胞定着液に関するものである。   The present invention relates to a cell release method, a cell release solution, a cell culture method, a cell culture solution, a cell solution, a cell solution preparation, a cell fixing method and a cell fixing solution using lactoferrin.

最近の医療技術や検査技術の進歩は著しく、新たな医療技術や新たな検査技術が次々と開発されてきている。新たな医療技術や新たな検査技術の開発では、細胞を用いた種々の実験・研究が行われている。   Recent advances in medical technology and testing technology are remarkable, and new medical technology and new testing technology have been developed one after another. In the development of new medical techniques and new testing techniques, various experiments and research using cells have been conducted.

細胞を用いた種々の実験・研究では、その目的に応じて必要な細胞数や培養皿枚数を用意する必要があるので、無処置の細胞(マスター細胞)を絶えず継代的に培養し続けなければならない。   In various experiments and research using cells, it is necessary to prepare the necessary number of cells and number of culture dishes according to the purpose, so it is necessary to continuously culture untreated cells (master cells) continuously. I must.

継代的に培養し続けたマスター細胞は、必要に応じて、培養皿から剥離後懸濁させ、一部は継代培養のために再度マスター細胞用の培養皿へ、また細胞懸濁液の残りは、実験・研究用に必要な細胞数を実験施行時までに満たすべく、増殖速度を計算しながら、それに適した大きさの、必要な枚数だけ、培養皿上に撒き、増殖させている。   If necessary, the master cells that have been continuously subcultured are detached from the culture dish and suspended if necessary, and part of the cells are again transferred to the master cell culture dish for subculture, and the cell suspension The rest is sowed and grown on the culture dish in the appropriate size and the necessary number while calculating the growth rate so that the number of cells required for the experiment / research will be met by the time of the experiment. .

マスター細胞を継代的に培養せず、毎回、液体窒素内で冷凍保存している細胞を起こして使用することも不可能ではないが、細胞を起こして実験に使えるように準備するのには時間がかかり過ぎるので、通常は上述したような継代的な培養方法が採られる。   It is not impossible to wake up cells that have been frozen and stored in liquid nitrogen each time without culturing the master cells, but to prepare the cells for use in experiments. Since it takes too much time, the subculture method as described above is usually employed.

目的の細胞数にまで増殖させた細胞は、その実験・研究の内容に合わせて利用する。ここで、増殖させた細胞は、培養皿上に接着させたまま利用する場合と、培養皿から剥離させて利用する場合がある。   Cells grown to the desired number of cells are used according to the content of the experiment and research. Here, the proliferated cells may be used while adhered on the culture dish or may be used after being detached from the culture dish.

培養皿から剥離させて利用する場合は、培養皿から細胞を剥離させなければならないが、培養皿から細胞を剥離させる方法としては、一般に、培養液中にトリプシンなどのタンパク質分解酵素を添加し、培養細胞の培養皿との結合部を溶かすことにより細胞を剥離させる方法が使用されている。そして、この方法において、剥離させる細胞に培養液の液流を吹き付けてフラッシングすることにより細胞を剥離させる方法も併せて採られることも有る。   When detaching from the culture dish, the cells must be detached from the culture dish.However, as a method of detaching the cells from the culture dish, generally, a protease such as trypsin is added to the culture solution, A method is used in which cells are detached by dissolving the joint of the cultured cells with the culture dish. And in this method, the method of peeling a cell by spraying the liquid flow of a culture solution on the cell to peel and flushing may be taken together.

しかし、トリプシンなどのタンパク質分解酵素を使用したり、培養液の液流を吹き付けてフラッシングをすると、培養細胞が損傷を受け、その機能回復に時間を要するという問題が有る。   However, if a proteolytic enzyme such as trypsin is used or flushing is performed by spraying a liquid flow of a culture solution, there is a problem that the cultured cells are damaged and it takes time to recover their functions.

また、種々の事情から、培養細胞を別の場所に輸送しなければならない場合が有る。培養細胞は培養器の内面から剥離すると死んでしまうので、輸送中に、細胞を培養したフラスコ内の培養液が揺れて培養細胞が剥離しないように、このフラスコに更に培養液を満たして培養液が揺れないようにしている。   Moreover, there are cases where the cultured cells have to be transported to another place due to various circumstances. Since cultured cells die when they are detached from the inner surface of the incubator, the culture solution in the flask in which the cells are cultured is shaken during transportation so that the cultured cells are not detached and the flask is further filled with the culture solution. Is trying not to shake.

しかし、このような対策を採っても、迅速に、しかも振動などの衝撃を加えないように注意して運搬しなければならないので、培養細胞の輸送は非常に面倒である。
特開2004−75547号公報 特開平8−66184号公報
However, even if such measures are taken, transportation of cultured cells is very troublesome because they must be transported promptly and carefully without applying shocks such as vibration.
JP 2004-75547 A JP-A-8-66184

解決しようとする課題は、接着性動物細胞を浮遊状態で正常に培養増殖させ、この培養増殖させた接着性動物細胞を所望の場所に再び定着させる方法が確立されていない点である。   The problem to be solved is that a method for culturing and growing adherent animal cells normally in a floating state and re-establishing the cultured and grown adherent animal cells at a desired location has not been established.

本発明に係る細胞遊離法は、細胞培養液中において接着性動物細胞を担体の表面に接着させた状態で培養し、その後ラクトフェリンを含む細胞遊離液と該細胞培養液とを混合して該担体から該接着性動物細胞を遊離させる細胞遊離法であって、該細胞培養液は血清を5〜20%の濃度範囲で含み、該細胞遊離液は該細胞培養液と混合した時のラクトフェリンの濃度が10〜500μMとなる濃度でラクトフェリンを含んでいることを特徴とするものである。   The cell release method according to the present invention is performed by culturing adherent animal cells in a cell culture solution while adhering to the surface of the carrier, and then mixing the cell release solution containing lactoferrin with the cell culture solution. Cell release method for releasing the adherent animal cells from the serum, wherein the cell culture solution contains serum in a concentration range of 5 to 20%, and the cell release solution has a concentration of lactoferrin when mixed with the cell culture solution. Is characterized by containing lactoferrin at a concentration of 10 to 500 μM.

ここで、血清の濃度を5〜20%としたのは、血清の濃度が5%未満あるいは20%を超えると細胞の増殖率が減少する不都合が生じるからである。また、ラクトフェリンの濃度を10〜500μMとしたのは、ラクトフェリンの濃度が10μM未満では細胞の遊離効果が少なく、500μMを超えると細胞の遊離効果が飽和してしまうからである。   Here, the reason that the serum concentration is 5 to 20% is that when the serum concentration is less than 5% or exceeds 20%, there is a disadvantage that the cell growth rate decreases. The reason why the concentration of lactoferrin is 10 to 500 μM is that when the concentration of lactoferrin is less than 10 μM, the cell release effect is small, and when the concentration exceeds 500 μM, the cell release effect is saturated.

また、前記細胞遊離液のラクトフェリンを除いた成分は、遊離させた細胞をそのまま培養させることができるという点で、前記細胞培養液の成分と略同一であることが好ましい。   Moreover, it is preferable that the component except the lactoferrin of the said cell free solution is substantially the same as the component of the said cell culture solution at the point that the released cell can be cultured as it is.

また、本発明に係る細胞遊離液は少なくともラクトフェリンを1〜10mM含む細胞培養液からなることを特徴とするものである。ここで、前記培養液中のラクトフェリンの濃度を1〜10mMとしたのは、ラクトフェリンの濃度をこの範囲にすれば、使い易いからである。   Moreover, the cell free solution according to the present invention is characterized by comprising a cell culture solution containing at least 1 to 10 mM of lactoferrin. Here, the reason why the concentration of lactoferrin in the culture solution is 1 to 10 mM is that if the concentration of lactoferrin is within this range, it is easy to use.

また、本発明に係る細胞培養法は、血清を5〜20%、ラクトフェリンを10〜500μM含む細胞培養液中で接着性動物細胞を浮遊状態で培養することを特徴とするものである。ここで、前記培養液中のラクトフェリンの濃度は10〜500μMが好ましい。ラクトフェリンの濃度を10〜500μMとしたのは、ラクトフェリンの濃度が10μM未満では細胞を浮遊培養する効果が少なくなって定着してしまい、500μMを超えると細胞を浮遊培養する効果が飽和してしまうからである。   The cell culture method according to the present invention is characterized by culturing adherent animal cells in a suspended state in a cell culture solution containing 5 to 20% serum and 10 to 500 μM lactoferrin. Here, the concentration of lactoferrin in the culture solution is preferably 10 to 500 μM. The reason why the concentration of lactoferrin is set to 10 to 500 μM is that if the concentration of lactoferrin is less than 10 μM, the effect of suspension culture of the cells is reduced and the effect is fixed, and if the concentration of lactoferrin exceeds 500 μM, the effect of suspension culture of the cells is saturated. It is.

また、本発明に係る細胞培養液は、血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とするものである。ここで、血清の濃度を5〜20%としたのは、血清の濃度が5%未満あるいは20%を超えると細胞の増殖率が減少する不都合が生じるからである。また、培養液中のラクトフェリンの濃度を10〜500μMとしたのは、ラクトフェリンの濃度が10μM未満では細胞を浮遊培養する効果が少なくなって定着してしまい、500μMを超えると細胞を浮遊培養する効果が飽和してしまうからである。   The cell culture medium according to the present invention is characterized by containing 5 to 20% serum and 10 to 500 μM lactoferrin. Here, the reason that the serum concentration is 5 to 20% is that when the serum concentration is less than 5% or exceeds 20%, there is a disadvantage that the cell growth rate decreases. In addition, the concentration of lactoferrin in the culture solution is set to 10 to 500 μM because if the concentration of lactoferrin is less than 10 μM, the effect of suspension culture of the cells is reduced and the effect is fixed. If the concentration of lactoferrin exceeds 500 μM, the effect of suspension culture of the cells is achieved. Is saturated.

また、本発明に係る細胞液は、血清を5〜20%、ラクトフェリンを10〜500μM含み、接着性動物細胞を浮遊状態で含む細胞培養液からなることを特徴とするものである。ここで、血清の濃度を5〜20%としたのは、血清の濃度が5%未満あるいは20%を超えると細胞の生存率が減少する不都合が生じるからである。また、培養液中のラクトフェリンの濃度を10〜500μMとしたのは、ラクトフェリンの濃度が10μM未満では細胞を浮遊させる効果が少なくなって定着してしまい、500μMを超えると細胞を浮遊させる効果が飽和してしまうからである。   The cell solution according to the present invention is characterized by comprising a cell culture solution containing 5 to 20% serum, 10 to 500 μM lactoferrin, and adhering animal cells in a floating state. Here, the reason that the serum concentration is 5 to 20% is that when the serum concentration is less than 5% or more than 20%, there is a disadvantage that the cell viability decreases. In addition, the concentration of lactoferrin in the culture solution is set to 10 to 500 μM because when the concentration of lactoferrin is less than 10 μM, the effect of floating the cells decreases and the effect of floating the cells is saturated, and when the concentration exceeds 500 μM, the effect of floating the cells is saturated. Because it will do.

また、本発明に係る細胞液製剤は、注射筒と、該注射筒内に充填された細胞液とからなり、該細胞液は、血清を5〜20%、ラクトフェリンを10〜500μM含み、更に接着性動物細胞を浮遊状態で含むことを特徴とするものである。ここで、血清の濃度を5〜20%としたのは、血清の濃度が5%未満あるいは20%を超えると細胞の生存率が減少する不都合が生じるからである。また、培養液中のラクトフェリンの濃度を10〜500μMとしたのは、ラクトフェリンの濃度が10μM未満では細胞を浮遊させる効果が少なくなって定着してしまい、500μMを超えると細胞を浮遊させる効果が飽和してしまうからである。   Moreover, the cell fluid preparation according to the present invention comprises a syringe barrel and a cell fluid filled in the syringe barrel, and the cell fluid contains 5 to 20% serum and 10 to 500 μM lactoferrin, and further adheres. It is characterized by containing sex animal cells in a suspended state. Here, the reason that the serum concentration is 5 to 20% is that when the serum concentration is less than 5% or more than 20%, there is a disadvantage that the cell viability decreases. In addition, the concentration of lactoferrin in the culture solution is set to 10 to 500 μM because when the concentration of lactoferrin is less than 10 μM, the effect of floating the cells decreases and the effect of floating the cells is saturated, and when the concentration exceeds 500 μM, the effect of floating the cells is saturated. Because it will do.

また、本発明に係る細胞定着法は、浮遊状態の接着性動物細胞及びラクトフェリンを含む細胞液を定着予定部に入れ、その後該定着予定部にラクトフェリンを含まない培養液を加えて該細胞液中のラクトフェリンの濃度を減じ、該定着予定部に該接着性動物細胞を定着させる細胞定着法であって、該細胞液が血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とするものである。   In the cell fixing method according to the present invention, a cell solution containing adhering animal cells in a floating state and lactoferrin is placed in a fixed part, and then a culture solution not containing lactoferrin is added to the fixed part. Cell fixing method in which the concentration of lactoferrin is reduced and the adherent animal cells are fixed in the part to be fixed, wherein the cell fluid contains 5 to 20% serum and 10 to 500 μM lactoferrin. It is.

ここで、ラクトフェリンを含まない培養液で濃度を減じられた前記細胞液中のラクトフェリンの濃度は10μM未満が好ましい。10μM未満では浮遊細胞の定着が顕著だからである。   Here, the concentration of lactoferrin in the cell solution reduced in concentration by a culture solution not containing lactoferrin is preferably less than 10 μM. This is because colonization of floating cells is remarkable at less than 10 μM.

また、本発明に係る別の細胞定着法は、定着予定部に浮遊状態の接着性動物細胞を含む細胞液を入れ、その後該定着予定部の細胞液に該接着性動物細胞の浮遊効果を失効させる失効物質を加えて、該定着予定部に該接着性動物細胞を定着させる細胞定着法であって、該細胞液が血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とするものである。   In another cell fixing method according to the present invention, a cell solution containing floating adherent animal cells is placed in a planned fixing portion, and then the floating effect of the adherent animal cells is abolished in the cell fluid of the planned fixing portion. A cell fixing method in which the adherent animal cells are fixed to the planned fixing portion by adding a revoking substance to be fixed, wherein the cell fluid contains 5 to 20% serum and 10 to 500 μM lactoferrin It is.

ここで、前記細胞定着液としては培養液中にグリコサミノグリカンを含んでいるものを使用することができる。また、浮遊状態の前記接着性動物細胞を定着させる際の前記細胞液中のグリコサミノグリカンの濃度は10〜500μg/mlが好ましい。グリコサミノグリカンの濃度が10μg/ml未満では浮遊細胞を定着させる効果が不充分であり、500μg/mlを超えると浮遊細胞を定着させる効果が飽和してしまうからである。   Here, as the cell fixing solution, a solution containing glycosaminoglycan in the culture solution can be used. Further, the concentration of glycosaminoglycan in the cell fluid when the adhering animal cells in a floating state are fixed is preferably 10 to 500 μg / ml. This is because if the concentration of glycosaminoglycan is less than 10 μg / ml, the effect of fixing floating cells is insufficient, and if it exceeds 500 μg / ml, the effect of fixing floating cells is saturated.

また、本発明に係る細胞定着液は、培養液中にグリコサミノグリカンを含有していることを特徴とするものである。   The cell fixing solution according to the present invention is characterized in that the culture solution contains glycosaminoglycan.

また、本発明に係る更に別の細胞定着法は、定着予定部に接着性動物細胞を定着させる定着物質を被覆し、その後浮遊状態の接着性動物細胞を含む細胞液を該定着予定部に入れ、該定着予定部に該接着性動物細胞を定着させる細胞定着法であって、該定着物質が細胞外マトリックスタンパク質であり、該細胞液が少なくとも血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とするものである。   Further, according to another cell fixing method of the present invention, a fixing substance for fixing an adherent animal cell is coated on the planned fixing portion, and then a cell solution containing the floating adherent animal cell is put in the fixed fixing portion. A cell fixing method in which the adherent animal cells are fixed on the part to be fixed, wherein the fixing substance is an extracellular matrix protein, and the cell fluid contains at least 5 to 20% serum and 10 to 500 μM lactoferrin. It is characterized by this.

ここで、前記失効剤としては細胞外マトリックスタンパク質を使用することができる。細胞外マトリックスタンパク質としては、例えば、浮遊細胞が神経細胞の場合、ラミニンを使用することができ、浮遊細胞が上皮系細胞や線維芽細胞といった他の細胞の場合、フィブロネクチンやコラーゲンを使用することができる。   Here, an extracellular matrix protein can be used as the terminator. As the extracellular matrix protein, for example, laminin can be used when floating cells are nerve cells, and fibronectin or collagen can be used when floating cells are other cells such as epithelial cells and fibroblasts. it can.

なお、上記各発明において、培養器とは、培養皿、培養フラスコ等、細胞を保持して培養することができる全ての器をいう。また、上記各発明において、接着性動物細胞とは、例えば神経細胞、グリア細胞、上皮細胞、各種の未分化細胞(間葉系細胞、幹細胞等)、ガン細胞等をいう。また、上記各発明において、培養液には、細胞を増殖させる養分を含んだもののみならず、生理食塩水のような細胞を単に保持させるだけのものも含まれる。   In each of the above inventions, the culture vessel refers to all vessels that can hold and culture cells, such as culture dishes and culture flasks. In each of the above inventions, the adherent animal cells refer to, for example, nerve cells, glial cells, epithelial cells, various undifferentiated cells (mesenchymal cells, stem cells, etc.), cancer cells and the like. In each of the above inventions, the culture solution includes not only those containing nutrients for growing cells but also those that simply hold cells such as physiological saline.

本発明によれば、培養させた接着性動物細胞を担体から損傷無く剥離させることができるという効果がある。また、遊離させた培養細胞に時間をかけて機能回復をさせる必要が無いので、損傷の無い培養細胞を迅速に得ることができるという効果がある。   According to the present invention, there is an effect that cultured animal animal cells can be detached from a carrier without damage. Moreover, since it is not necessary to restore the function of the cultured cells that have been released over time, there is an effect that it is possible to quickly obtain cultured cells that are not damaged.

また、本発明によれば、浮遊している細胞が接着している細胞と比べて細胞増殖能力が高く、しかも細胞を浮遊状態で正常に培養することができるので、損傷の無い正常な細胞を迅速且つ大量に得ることができるという効果がある。   In addition, according to the present invention, since the cell proliferation ability is higher than that of the cell to which the floating cell is adhered, and the cell can be normally cultured in the floating state, There is an effect that it can be obtained quickly and in large quantities.

また、本発明によれば、細胞を浮遊状態で培養することができるので、培養細胞を容易に輸送運搬することができるという効果がある。   Further, according to the present invention, since the cells can be cultured in a floating state, there is an effect that the cultured cells can be easily transported and transported.

また、本発明によれば、ラクトフェリンを希釈したり、ラミニンを被覆した培養器に培養液を移したり、グリコサミノグリカンを添加するだけという簡単な方法で、浮遊状態の細胞から定着状態の細胞を容易に得ることができるという効果がある。   In addition, according to the present invention, a simple method of diluting lactoferrin, transferring a culture solution to a laminin-coated incubator, or adding glycosaminoglycan can be performed from a floating cell to a fixed cell. Can be easily obtained.

接着性動物細胞を浮遊状態で培養増殖させ、これを再び所望の場所に定着させるという目的をラクトフェリンとグリコサミノグリカンを利用することにより実現した。   The purpose of culturing and growing adherent animal cells in a floating state and re-establishing them in a desired place was realized by using lactoferrin and glycosaminoglycan.

ここで、ラクトフェリン(Lactoferrin)は乳中から見いだされた分子量約80kDのタンパク質で、種々の糖鎖構造と親和性を有し、細胞表層のタンパク質やグリコサミノグリカンと結合する性質をもち、細菌、ウイルス、原虫などの微生物感染の抑制や抗炎症作用などの様々な効果を有することで注目されている。   Here, lactoferrin is a protein with a molecular weight of about 80 kD found in milk, has various sugar chain structures and affinity, has the property of binding to cell surface proteins and glycosaminoglycans, It has attracted attention for its various effects such as suppression of microbial infections such as viruses and protozoa, and anti-inflammatory action.

本件発明者は、ラクトフェリンの神経細胞に対する影響を調べる目的で、神経細胞の研究に広く用いられているラット副腎髄質褐色細胞種腫由来のPC12細胞の培地にウシラクトフェリン(bLf)を添加しその影響について調べた。   The present inventor added bovine lactoferrin (bLf) to a medium of rat adrenal medullary pheochromocytoma-derived PC12 cells, which is widely used in the study of nerve cells, for the purpose of examining the effects of lactoferrin on neurons. Investigated about.

培養液を入れた複数の培養皿を準備し、培養皿一皿当たり7×10のPC12細胞を撒き、このPC12細胞を、5%CO雰囲気下、37℃で72時間培養した。ここで、培養液はDMEM(Dulbecco's Modified Eagle Medium)培地{5%(v/v)非加熱horse serum、 5%(v/v)非加熱fetal bovine serum、 1×10units/l penicillin G Sodium、 1×10mg/l streptomycin sulfate、 0.044M NaHCO3}を使用し、PC12細胞は理化学研究所細胞開発銀行から分譲を受けたものを使用した。Prepare plurality of culture dishes in culture medium, plated PC12 cells culture dish dish per 7 × 10 4, the PC12 cells, 5% CO 2 atmosphere, for 72 hours at 37 ° C.. Here, DMEM (Dulbecco's Modified Eagle Medium) medium {5% (v / v) unheated horse serum, 5% (v / v) unheated fetal bovine serum, 1 × 10 5 units / l penicillin G Sodium 1 × 10 5 mg / l streptomycin sulfate, 0.044M NaHCO 3 } was used, and PC12 cells were used from RIKEN Cell Development Bank.

72時間培養後、培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が0μM〜500μMとなるように添加した。ここで、培養液に添加したウシラクトフェリン(bLf)は培養液で予め希釈したものを使用した。希釈液中のウシラクトフェリン(bLf)の濃度は1〜10mMのものが使い易い。なお、ラクトフェリンは培養液で希釈したものでなく、生理食塩水等、栄養分を含まない液で希釈したものを用いても良い。   After culturing for 72 hours, bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 0 μM to 500 μM. Here, bovine lactoferrin (bLf) added to the culture solution was diluted beforehand with the culture solution. The concentration of bovine lactoferrin (bLf) in the diluted solution is easily 1 to 10 mM. Note that lactoferrin is not diluted with a culture solution, but may be diluted with a solution containing no nutrients such as physiological saline.

ウシラクトフェリン(bLf)を添加して24時間経過後、培養器内の培養液を顕微鏡で観察したところ、浮遊しているPC12細胞が観察された。そして、波長570nmにおけるこの培養液の吸光度(O.D.)を細胞賦活評価試験(MTT assay)により測定して、培養液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べたところ、図1のグラフに示す通りであった。   24 hours after adding bovine lactoferrin (bLf), the culture solution in the incubator was observed with a microscope, and floating PC12 cells were observed. The absorbance (OD) of this culture solution at a wavelength of 570 nm was measured by a cell activation evaluation test (MTT assay), and the number of cells released in the culture solution {the number of cells is proportional to the absorbance (OD). It was as shown in the graph of FIG.

図1に示す結果から、ウシラクトフェリン(bLf)は濃度が10μMを超えるとPC12細胞の培養皿上への接着を阻害し、細胞を遊離・浮遊させる作用を有することがわかる。また、培養液中に浮遊している細胞数はウシラクトフェリン(bLf)の濃度の増加に従って増加するが、濃度が500μMを超えるとその作用は飽和することがわかる。   From the results shown in FIG. 1, it can be seen that bovine lactoferrin (bLf) has the effect of inhibiting the adhesion of PC12 cells onto the culture dish and freeing and floating the cells when the concentration exceeds 10 μM. Further, the number of cells floating in the culture medium increases as the concentration of bovine lactoferrin (bLf) increases, but it can be seen that the action is saturated when the concentration exceeds 500 μM.

なお、ウシラクトフェリン(bLf)は分子量約80kDで陽電荷に帯電することから、これらの物理的性質が上記の作用を及ぼしている可能性も考えられる。そこで、上記の作用がウシラクトフェリン(bLf)に特異的であることを確認するために、ウシラクトフェリン(bLf)の代わりにウシラクトフェリン(bLf)と同様に分子量の大きいタンパク質であるウシ血清アルブミン(67kD)および陽電荷をもつタンパク質であるリゾチーム(14kD)に対する影響についてもウシラクトフェリン(bLf)と同様に調べた。   Since bovine lactoferrin (bLf) is charged with a positive charge at a molecular weight of about 80 kD, it is possible that these physical properties may have the above effects. Therefore, in order to confirm that the above action is specific to bovine lactoferrin (bLf), bovine serum albumin (67 kD) which is a protein having a large molecular weight in the same manner as bovine lactoferrin (bLf) instead of bovine lactoferrin (bLf). ) And lysozyme (14 kD), which is a positively charged protein, were also examined in the same manner as bovine lactoferrin (bLf).

しかし、ウシ血清アルブミン(67kD)、リゾチーム(14kD)にウシラクトフェリン(bLf)で認められたような細胞を培養皿から遊離させる作用は認められなかった。従って、PC12細胞を培養皿から遊離させる作用はウシラクトフェリン(bLf)に特異的なもので、高分子量や電荷がもたらすものではないことがわかる。   However, no action was observed on the bovine serum albumin (67 kD) and lysozyme (14 kD) to release cells from the culture dish as observed with bovine lactoferrin (bLf). Therefore, it can be seen that the action of releasing PC12 cells from the culture dish is specific to bovine lactoferrin (bLf) and is not caused by high molecular weight or charge.

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、更に12時間培養し、波長570nmにおけるこの培養液の吸光度(O.D.)をMTT assayにより0.5h、1h、3h、6h、12hと経時的に測定して、培養液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を時間毎に調べた。結果は図2に示す通りであった。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture medium in the culture dish so that the concentration in the culture medium was 100 μM, and further cultured for 12 hours, with a wavelength of 570 nm. The absorbance (OD) of this culture solution was measured with the MTT assay as 0.5h, 1h, 3h, 6h, 12h over time, and the number of cells released in the culture solution {the number of cells is the absorbance ( Which is proportional to OD) was examined every hour. The result was as shown in FIG.

この図2に示された結果から、ウシラクトフェリン(bLf)の濃度100μMの条件下では、培養皿の底面に定着していた細胞はウシラクトフェリン(bLf)の働きにより0.5h当たりから少し遊離し、3hでかなり遊離し、6hで殆どが遊離することがわかる。   From the results shown in FIG. 2, under the condition of bovine lactoferrin (bLf) concentration of 100 μM, the cells that had settled on the bottom of the culture dish were released a little from 0.5 h by the action of bovine lactoferrin (bLf). It can be seen that it is quite liberated in 3h and almost free in 6h.

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、24時間経過させた。この経過によって培養皿の内面に定着した状態で増殖していた細胞は培養皿の内面から遊離し、培養液中に浮遊することになる。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 100 μM, and allowed to pass for 24 hours. Through this process, the cells proliferating in a state of being fixed on the inner surface of the culture dish are released from the inner surface of the culture dish and float in the culture solution.

次に、培養液中に浮遊している細胞を回収し、予め用意しておいた培養皿、すなわち培養液中にウシラクトフェリン(bLf)が100μM濃度で存在する培養皿{bLf(+)}と、培養液中にウシラクトフェリン(bLf)が存在しない培養皿{bLf(-)}に、回収したこの細胞を移し、144時間まで更に培養し、波長570nmにおけるこの培養液の吸光度(O.D.)をMTT assayにより経時的に測定し、培養液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べた。結果は図3に示す通りであった。   Next, cells floating in the culture medium are collected, and a culture dish prepared in advance, that is, a culture dish {bLf (+)} in which bovine lactoferrin (bLf) is present at a concentration of 100 μM in the culture liquid, The collected cells are transferred to a culture dish {bLf (−)} in which bovine lactoferrin (bLf) is not present in the culture medium, and further cultured for up to 144 hours. The absorbance (OD) of this culture liquid at a wavelength of 570 nm is measured with MTT. The number of cells released in the culture broth (the number of cells is proportional to the absorbance (OD)) was determined by measurement over time. The result was as shown in FIG.

図3のbLf(+)に示す結果から、浮遊細胞はウシラクトフェリン(bLf)の濃度が100μMの環境下において、浮遊状態で時間と共に増殖することがわかる。   From the results shown in bLf (+) in FIG. 3, it is found that the floating cells proliferate with time in a floating state in an environment where the concentration of bovine lactoferrin (bLf) is 100 μM.

また、図3のbLf(+)、bLf(−)に示す結果から、ウシラクトフェリン(bLf)を含む培養液{bLf(+)}の吸光度(O.D.)とウシラクトフェリン(bLf)を含まない培養液{bLf(-)}の吸光度(O.D.)とを比較すると、ウシラクトフェリン(bLf)を含む培養液{bLf(+)}の吸光度(O.D.)が高いこと、すなわちウシラクトフェリン(bLf)を含む培養液{bLf(+)}中における細胞の方がウシラクトフェリン(bLf)を含まない培養液{bLf(-)}中における細胞より細胞増殖能力が高いことがわかる。   Further, from the results shown in bLf (+) and bLf (−) in FIG. 3, the absorbance (OD) of the culture solution {bLf (+)} containing bovine lactoferrin (bLf) and the culture solution containing no bovine lactoferrin (bLf). When the absorbance (OD) of {bLf (-)} is compared, the absorbance (OD) of the culture solution {bLf (+)} containing bovine lactoferrin (bLf) is high, that is, the culture solution containing bovine lactoferrin (bLf) It can be seen that the cells in {bLf (+)} have a higher cell growth ability than the cells in the culture solution {bLf (−)} not containing bovine lactoferrin (bLf).

また、浮遊細胞を培養した培養液(以下、「細胞液」という。)を注射筒に充填し、これを37℃で12時間保持し、その後、波長570nmにおけるこの培養液の吸光度(O.D.)をMTT assayにより測定して、細胞液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べたところ、細胞は生存しており、その数は増殖により保持前と比べて1.1倍に増加していた。   Moreover, a culture solution (hereinafter referred to as “cell solution”) in which floating cells are cultured is filled into a syringe, and this is held at 37 ° C. for 12 hours. Thereafter, the absorbance (OD) of this culture solution at a wavelength of 570 nm is measured. When the number of cells released in the cell fluid (the number of cells is proportional to the absorbance (OD)) was measured by MTT assay, the cells were alive and the number was increased by proliferation. It increased 1.1 times compared with before the retention.

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、24時間経過させた。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 100 μM, and allowed to pass for 24 hours.

次に、培養液中に浮遊している細胞を回収し、ウシラクトフェリン(bLf)の濃度が0μM、100μM、300μM、500μM、600μMの培養液を入れた各培養皿に移し、24時間培養した。そして、波長570nmにおけるこの各培養皿の培養液の吸光度(O.D.)をMTT assayにより測定し、各培養皿の培養液中に浮遊している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べた。結果は図4に示す通りであった。   Next, the cells floating in the culture solution were collected, transferred to each culture dish containing culture solutions having bovine lactoferrin (bLf) concentrations of 0 μM, 100 μM, 300 μM, 500 μM, and 600 μM, and cultured for 24 hours. Then, the absorbance (OD) of the culture medium in each culture dish at a wavelength of 570 nm was measured by MTT assay, and the number of cells floating in the culture liquid of each culture dish {the number of cells was proportional to the absorbance (OD). I checked}. The result was as shown in FIG.

図4に示す結果から、培養液中のウシラクトフェリン(bLf)の濃度を高くすると細胞の増殖能力が高くなることがわかる。   From the results shown in FIG. 4, it can be seen that when the concentration of bovine lactoferrin (bLf) in the culture solution is increased, the proliferation ability of the cells is increased.

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、24時間経過させた。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 100 μM, and allowed to pass for 24 hours.

次に、ウシラクトフェリン(bLf)の添加によって浮遊状態の細胞を含むようになった培養液を別の各培養皿に移し、そこにウシラクトフェリン(bLf)を含まない培養液を加え、ウシラクトフェリン(bLf)の濃度を10〜100μMまで各々低減させ、更に37℃で24時間経過させた。この経過により培養皿の底面に細胞が定着しているのが目視で観察された。   Next, the culture solution that has become suspended cells by the addition of bovine lactoferrin (bLf) is transferred to another culture dish, to which a culture solution that does not contain bovine lactoferrin (bLf) is added, and bovine lactoferrin ( The concentration of bLf) was reduced to 10 to 100 μM, and the mixture was further allowed to pass at 37 ° C. for 24 hours. Through this process, it was visually observed that cells were fixed on the bottom of the culture dish.

次に、培養皿の培養液を捨て、培養皿の内面を洗浄液で洗い、波長570nmにおけるこの洗浄液の吸光度(O.D.)を各培養皿毎にMTT assayにより測定し、洗浄液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べたところ、図5に示す通りであった。   Next, the culture solution in the culture dish is discarded, the inner surface of the culture dish is washed with a washing solution, and the absorbance (OD) of this washing solution at a wavelength of 570 nm is measured for each culture dish by MTT assay, and the cells released in the washing solution. The number of cells {the number of cells is proportional to the absorbance (OD)} was as shown in FIG.

図5に示す結果から、ウシラクトフェリン(bLf)を含まない希釈液で希釈して培養液中のウシラクトフェリン(bLf)の濃度を減ずると、培養液中に浮遊していた細胞が培養皿の内面に再び定着することがわかる。   From the results shown in FIG. 5, when the concentration of bovine lactoferrin (bLf) in the culture solution is reduced by diluting with a diluent not containing bovine lactoferrin (bLf), the cells suspended in the culture solution are removed from the inner surface of the culture dish. It can be seen that it settles again.

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、24時間経過させた。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 100 μM, and allowed to pass for 24 hours.

次に、ウシラクトフェリン(bLf)の添加によって浮遊状態の細胞を含むようになった培養液を別の培養皿に移し、そこにヘパリンやコンドロイチン硫酸A,Cなどのグリコサミノグリカンを含む培養液(細胞定着液)を1〜500μg/mlの範囲で添加し、更に24時間経過させた。この経過により培養皿の底面にPC12細胞が定着しているのが目視で観察された。   Next, the culture solution containing suspended cells by the addition of bovine lactoferrin (bLf) is transferred to another culture dish, and the culture solution contains glycosaminoglycans such as heparin and chondroitin sulfate A and C. (Cell fixing solution) was added in the range of 1 to 500 μg / ml, and further allowed to pass for 24 hours. It was visually observed that PC12 cells were fixed on the bottom of the culture dish during this process.

次に、波長570nmにおけるこの培養皿中の培養液の吸光度(O.D.)を各培養皿毎にMTT assayにより測定し、培養液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べたところ、図6に示す通りであった。   Next, the absorbance (OD) of the culture solution in this culture dish at a wavelength of 570 nm was measured for each culture dish by MTT assay, and the number of cells released in the culture solution {the number of cells is the absorbance (OD). It is as shown in FIG.

図6に示す結果から、ヘパリンやコンドロイチン硫酸などのグリコサミノグリカンを含む培養液(細胞定着液)を添加すると、培養液中に浮遊していた細胞数が減少すること、すなわち、培養液中に浮遊していた細胞が培養皿の内面に再び定着することがわかった。   From the results shown in FIG. 6, when a culture solution (cell fixing solution) containing glycosaminoglycan such as heparin or chondroitin sulfate is added, the number of cells suspended in the culture solution is reduced. It was found that the cells that had been suspended in the colony settled again on the inner surface of the culture dish.

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、24時間経過させた。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 100 μM, and allowed to pass for 24 hours.

次に、ウシラクトフェリン(bLf)の添加によって浮遊状態の細胞を含むようになった培養液を、予め用意したラミニンで内面を被覆した培養皿(Lam+)とラミニンで内面を被覆してない培養皿(Lam−)に移し、更に24時間経過させた。   Next, the culture medium that contains floating cells by the addition of bovine lactoferrin (bLf) is prepared by using a pre-prepared laminin-coated culture dish (Lam +) and a laminin-coated culture dish. (Lam-) and further 24 hours passed.

次に、波長570nmにおけるこの培養皿中の培養液の吸光度(O.D.)をMTT assayにより経時的に測定し、培養液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べた。結果は図7に示す通りであった。   Next, the absorbance (OD) of the culture solution in this culture dish at a wavelength of 570 nm was measured over time by MTT assay, and the number of cells released in the culture solution {the number of cells was proportional to the absorbance (OD). I checked}. The result was as shown in FIG.

また、培養皿の内面を観察したところ、培養皿の内面にはPC12細胞が定着し、増殖しているのが確認された。以上のことから、培養液中に浮遊していた細胞はウシラクトフェリン(bLf)の存在下でラミニンの働きにより培養皿の底面に定着することがわかる。   Further, when the inner surface of the culture dish was observed, it was confirmed that PC12 cells were fixed and proliferated on the inner surface of the culture dish. From the above, it can be seen that the cells suspended in the culture solution are fixed to the bottom of the culture dish by the action of laminin in the presence of bovine lactoferrin (bLf).

実施例1と同様にしてPC12細胞を72時間培養し、その後培養皿の培養液にウシラクトフェリン(bLf)を培養液中の濃度が100μMとなるように添加し、24時間経過させた。   PC12 cells were cultured for 72 hours in the same manner as in Example 1, and then bovine lactoferrin (bLf) was added to the culture solution in the culture dish so that the concentration in the culture solution was 100 μM, and allowed to pass for 24 hours.

次に、ウシラクトフェリン(bLf)の添加によって浮遊状態の細胞を含むようになった培養液を、予め用意したラミニンで内面を被覆した培養皿(Lam+)、フィブロネクチンで内面を被覆した培養皿(Lam−)、何も被覆してない培養皿(non-coat)に移し、更に24時間培養し、波長570nmにおけるこの培養皿中の培養液の吸光度(O.D.)を各培養皿毎にMTT assayにより測定し、培養液中に遊離している細胞の数{細胞の数は吸光度(O.D.)に比例している}を調べた。   Next, the culture medium containing suspended cells by the addition of bovine lactoferrin (bLf) was prepared by using a previously prepared laminin-coated culture dish (Lam +) or fibronectin-coated culture dish (Lam). -), Moved to a non-coat culture dish (non-coat), further cultured for 24 hours, and the absorbance (OD) of the culture medium in this culture dish at a wavelength of 570 nm was measured for each culture dish by MTT assay. Then, the number of cells released in the culture solution (the number of cells is proportional to the absorbance (OD)) was examined.

結果は図8に示す通りであり、ラミニンを被覆した方の培養皿中の培養液中の浮遊細胞は大幅に減少しており、ラミニンを被覆してない方の培養液中の浮遊細胞は減少しなかった。また、培養皿の内面を観察したところ、培養皿の内面にはPC12細胞が定着し、増殖しているのが確認された。   The results are as shown in FIG. 8. The floating cells in the culture medium in the culture dish coated with laminin are greatly reduced, and the floating cells in the culture liquid not coated with laminin are reduced. I did not. Further, when the inner surface of the culture dish was observed, it was confirmed that PC12 cells were fixed and proliferated on the inner surface of the culture dish.

ラミニンを被覆した培養皿に移した浮遊細胞は100μMのウシラクトフェリン(bLf)存在下にもかかわらず、浮遊細胞数が減少し、培養皿底面に定着して発育する細胞数が増加した(bLf+,Lam+)。ところが、フィブロネクチンを被覆した培養皿に移した浮遊細胞は、浮遊状態を維持し発育した(bLf+,FN+)。従って、ウシラクトフェリン(bLf)の神経細胞に対する接着抑制効果は、神経細胞に発現するインテグリンとラミニン間で形成されるインテグリン依存性の細胞接着には無効であることがわかる。   Despite the presence of 100 μM bovine lactoferrin (bLf), the floating cells transferred to the laminin-coated culture dish decreased in number, and the number of cells that grew on the bottom of the culture dish increased (bLf +, Lam +). However, the floating cells transferred to the fibronectin-coated culture dish maintained the floating state and developed (bLf +, FN +). Therefore, it can be seen that the adhesion inhibitory effect of bovine lactoferrin (bLf) on neurons is ineffective for integrin-dependent cell adhesion formed between integrins expressed in neurons and laminin.

ウシラクトフェリン(bLf)がPC12細胞に直接結合して作用していることを確認するために、PC12細胞にビオチン化bLf(b−bLf)を添加し、24時間後に全細胞を回収・洗浄し、細胞を可溶化後、SDSポリアクリルアミド電気泳導に供し、さらにナイトロセルロース膜にブロットした後にb−bLfの結合を解析した。泳動パターンは図9に示す通りとなった。   In order to confirm that bovine lactoferrin (bLf) acts directly on PC12 cells, biotinylated bLf (b-bLf) was added to PC12 cells, and after 24 hours, all cells were collected and washed. The cells were solubilized, subjected to SDS polyacrylamide electrophoresis, and blotted onto a nitrogen cellulose membrane, and then analyzed for b-bLf binding. The electrophoretic pattern was as shown in FIG.

図9において、(a)はb−bLf単独処置、(b)はb−bLf+bLf 100 μM、(c)はb−bLf+bLf 500 μM、(d)はb−bLf+BSA100 μM、(e)はb−bLf+BSA500 μMである。   In FIG. 9, (a) is treated with b-bLf alone, (b) is b-bLf + bLf 100 μM, (c) is b-bLf + bLf 500 μM, (d) is b-bLf + BSA 100 μM, (e) is b -BLf + BSA 500 μM.

解析の結果、b−bLfが検出され、b−bLfがPC12細胞に直接結合して作用していることがわかった。   As a result of the analysis, b-bLf was detected, and it was found that b-bLf was directly acting on PC12 cells.

細胞の浮遊と定着の機構を制御する手段の研究を解明することにより、ヒトや動物の生体組織を再生させる用途にも適用できる可能性がある。   By elucidating research on means for controlling the mechanism of cell floating and colonization, it may be applicable to the regeneration of living tissues of humans and animals.

培養液中のウシラクトフェリン(bLf)の濃度(μM)と培養液の吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the density | concentration (micromol) of the bovine lactoferrin (bLf) in a culture solution, and the light absorbency (O.D.) of a culture solution. 培養液中にウシラクトフェリン(bLf)を添加してからの経過時間と培養液の吸光度(O.D.)との関係を示すグラフである。2 is a graph showing the relationship between the elapsed time after adding bovine lactoferrin (bLf) to the culture solution and the absorbance (O.D.) of the culture solution. 回収した細胞を別の培養皿培養液中にて培養を開始してからの時間と吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the time after starting culture | cultivation of the collect | recovered cell in another culture dish culture solution, and light absorbency (O.D.). 培養液中のウシラクトフェリン(bLf)の濃度(μM)と培養液の吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the density | concentration (micromol) of the bovine lactoferrin (bLf) in a culture solution, and the light absorbency (O.D.) of a culture solution. 培養液中のウシラクトフェリン(bLf)の濃度(μM)と培養液の吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the density | concentration (micromol) of the bovine lactoferrin (bLf) in a culture solution, and the light absorbency (O.D.) of a culture solution. グリコサミノグリカンの添加量(μg/ml)と培養液の吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the addition amount (microgram / ml) of glycosaminoglycan, and the light absorbency (O.D.) of a culture solution. ラミニンの有無と培養液の吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the presence or absence of laminin, and the light absorbency (O.D.) of a culture solution. ラミニンの有無及びフィブロネクチンの有無と培養液の吸光度(O.D.)との関係を示すグラフである。It is a graph which shows the relationship between the presence or absence of laminin and the presence or absence of fibronectin, and the light absorbency (O.D.) of a culture solution. b−bLfと各濃度のbLfあるいはBSA存在下で培養したPC12細胞を洗浄後可溶化し、電気泳動したときのb+bLfの泳動パターンを示す図である。It is a figure which shows the electrophoretic pattern of b + bLf when PC12 cell cultured in b-bLf and bLf of each density | concentration presence or BSA is wash | cleaned and electrophoresed.

Claims (15)

細胞培養液中において接着性動物細胞を担体の表面に接着させた状態で培養し、その後ラクトフェリンを含む細胞遊離液と該細胞培養液とを混合して該担体から該接着性動物細胞を遊離させる細胞遊離法であって、該細胞培養液は血清を5〜20%の濃度範囲で含み、該細胞遊離液は該細胞培養液と混合した時のラクトフェリンの濃度が10〜500μMとなる濃度でラクトフェリンを含んでいることを特徴とする細胞遊離法。   Culturing the adherent animal cells in the cell culture medium in a state of adhering to the surface of the carrier, and then mixing the cell free solution containing lactoferrin and the cell culture solution to release the adherent animal cells from the carrier. In the cell release method, the cell culture solution contains serum in a concentration range of 5 to 20%, and the cell release solution has a lactoferrin concentration at a concentration of 10 to 500 μM when mixed with the cell culture solution. A cell release method comprising: 前記細胞遊離液のラクトフェリンを除いた成分が前記細胞培養液の成分と略同一であることを特徴とする請求項1に記載の細胞遊離法。   The cell release method according to claim 1, wherein the components of the cell free solution excluding lactoferrin are substantially the same as the components of the cell culture solution. 血清を5〜20%、ラクトフェリンを1〜10mM含む細胞培養液からなることを特徴とする細胞遊離液。   A cell free solution comprising a cell culture solution containing 5 to 20% serum and 1 to 10 mM lactoferrin. 血清を5〜20%、ラクトフェリンを10〜500μM含む細胞培養液中で接着性動物細胞を浮遊状態で培養することを特徴とする細胞培養法。   A cell culture method characterized by culturing adherent animal cells in a suspended state in a cell culture medium containing 5 to 20% serum and 10 to 500 µM lactoferrin. 血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とする細胞培養液。   A cell culture medium comprising 5 to 20% serum and 10 to 500 μM lactoferrin. 血清を5〜20%、ラクトフェリンを10〜500μM含み、接着性動物細胞を浮遊状態で含む細胞培養液からなることを特徴とする細胞液。   A cell solution comprising a cell culture solution containing 5 to 20% serum, 10 to 500 μM lactoferrin and containing adherent animal cells in a suspended state. 注射筒と、該注射筒内に充填された細胞液とからなり、該細胞液は、血清を5〜20%、ラクトフェリンを10〜500μM含み、更に接着性動物細胞を浮遊状態で含むことを特徴とする細胞液製剤。   It is composed of a syringe barrel and a cell fluid filled in the syringe barrel, and the cell fluid contains 5 to 20% serum, 10 to 500 μM lactoferrin, and further contains adherent animal cells in a floating state. A cell fluid preparation. 浮遊状態の接着性動物細胞及びラクトフェリンを含む細胞液を定着予定部に入れ、その後該定着予定部にラクトフェリンを含まない細胞培養液を加えて該細胞液中のラクトフェリンの濃度を減じ、該定着予定部に該接着性動物細胞を定着させる細胞定着法であって、該細胞液が血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とする細胞定着法。   A cell solution containing floating adhering animal cells and lactoferrin is placed in the planned fixing part, and then a cell culture solution not containing lactoferrin is added to the planned fixing part to reduce the concentration of lactoferrin in the cell liquid, and the fixing planned A cell fixing method for fixing the adherent animal cells to a part, wherein the cell solution contains 5 to 20% of serum and 10 to 500 μM of lactoferrin. ラクトフェリンを含まない培養液で濃度を減じられた前記細胞液中のラクトフェリンの濃度が10μM未満であることを特徴とする請求項8に記載の細胞定着法。   The cell fixing method according to claim 8, wherein the concentration of lactoferrin in the cell solution reduced in concentration by a culture solution not containing lactoferrin is less than 10 μM. 定着予定部に浮遊状態の接着性動物細胞を含む細胞液を入れ、その後該定着予定部の細胞液に該接着性動物細胞の浮遊効果を失効させる失効物質を加えて、該定着予定部に該接着性動物細胞を定着させる細胞定着法であって、該細胞液が血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とする細胞定着法。   A cell solution containing floating adherent animal cells is placed in the planned fixing portion, and then a revoking substance that invalidates the floating effect of the adherent animal cells is added to the cell fluid in the planned fixing portion, and A cell fixing method for fixing adherent animal cells, wherein the cell fluid contains 5 to 20% of serum and 10 to 500 μM of lactoferrin. 前記失効物質がグリコサミノグリカンであることを特徴とする請求項10に記載の細胞定着法。   The cell fixing method according to claim 10, wherein the lapsed substance is glycosaminoglycan. 浮遊状態の前記接着性動物細胞を定着させる際の前記細胞液中のグリコサミノグリカンの濃度が10〜500μg/mlであることを特徴とする請求項11に記載の細胞定着法。   12. The cell fixing method according to claim 11, wherein the concentration of glycosaminoglycan in the cell fluid when the adherent animal cells in a floating state are fixed is 10 to 500 μg / ml. グリコサミノグリカンを含む細胞培養液からなることを特徴とする細胞定着液。   A cell fixing solution comprising a cell culture solution containing glycosaminoglycan. 定着予定部に接着性動物細胞を定着させる定着物質を被覆し、その後浮遊状態の接着性動物細胞を含む細胞液を該定着予定部に入れ、該定着予定部に該接着性動物細胞を定着させる細胞定着法であって、該定着物質が細胞外マトリックスタンパク質であり、該細胞液が少なくとも血清を5〜20%、ラクトフェリンを10〜500μM含むことを特徴とする細胞定着法。   A fixing material for fixing the adherent animal cells is coated on the planned fixing portion, and then a cell solution containing the floating adhering animal cells is placed in the fixed fixing portion, and the adhesive animal cells are fixed on the planned fixing portion. A cell fixing method, wherein the fixing substance is an extracellular matrix protein, and the cell fluid contains at least 5 to 20% serum and 10 to 500 μM lactoferrin. 前記細胞外マトリックスタンパク質がラミニンであることを特徴とする請求項14に記載の細胞定着法。   The cell colonization method according to claim 14, wherein the extracellular matrix protein is laminin.
JP2007512410A 2005-04-05 2006-01-19 Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution Active JP4724836B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007512410A JP4724836B2 (en) 2005-04-05 2006-01-19 Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005108157 2005-04-05
JP2005108157 2005-04-05
JP2007512410A JP4724836B2 (en) 2005-04-05 2006-01-19 Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution
PCT/JP2006/300698 WO2006109367A1 (en) 2005-04-05 2006-01-19 Cell release method, cell release solution, cell culture method, cell culture medium, cell solution, cell solution preparation, cell colonization method and cell colonization solution

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010226141A Division JP2011011077A (en) 2005-04-05 2010-10-06 Cell colonization solution

Publications (2)

Publication Number Publication Date
JPWO2006109367A1 true JPWO2006109367A1 (en) 2008-10-02
JP4724836B2 JP4724836B2 (en) 2011-07-13

Family

ID=37086661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007512410A Active JP4724836B2 (en) 2005-04-05 2006-01-19 Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution
JP2010226141A Pending JP2011011077A (en) 2005-04-05 2010-10-06 Cell colonization solution

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010226141A Pending JP2011011077A (en) 2005-04-05 2010-10-06 Cell colonization solution

Country Status (2)

Country Link
JP (2) JP4724836B2 (en)
WO (1) WO2006109367A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102359148B1 (en) * 2014-01-23 2022-02-08 닛산 가가쿠 가부시키가이샤 Culture medium composition
KR102250401B1 (en) * 2020-01-02 2021-05-11 주식회사 바이오솔루션 Conditioned medium containing high concentration of extracellular vesicles bound to lactoferrin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502385A (en) * 1990-10-05 1993-04-28 システミックス,インコーポレイティド Growth, production and composition of megakaryocytes and platelets
JP2947488B2 (en) * 1990-12-29 1999-09-13 雪印乳業株式会社 Serum-free medium for suspension culture of adherent animal cells and suspension culture method using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104787A (en) * 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
FR2726574B1 (en) * 1994-11-04 1997-01-17 Univ Paris Curie PROCESS FOR DISSOCIATION OF EUKARYOTIC CELLS IN CULTURE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502385A (en) * 1990-10-05 1993-04-28 システミックス,インコーポレイティド Growth, production and composition of megakaryocytes and platelets
JP2947488B2 (en) * 1990-12-29 1999-09-13 雪印乳業株式会社 Serum-free medium for suspension culture of adherent animal cells and suspension culture method using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010042583, 第139 回日本獣医学会学術集会講演要旨集, 20050301, 226 (JP−101) *
JPN6010042584, Biosci. Biotechnol. Biochem., 1992, vol. 56, 965−966 *

Also Published As

Publication number Publication date
JP4724836B2 (en) 2011-07-13
JP2011011077A (en) 2011-01-20
WO2006109367A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
JP6850456B2 (en) How to purify retinal pigment epithelial cells
Shojaie et al. Acellular lung scaffolds direct differentiation of endoderm to functional airway epithelial cells: requirement of matrix-bound HS proteoglycans
US11229725B2 (en) Cell repopulated collagen matrix for soft tissue repair and regeneration
JP2021104021A (en) Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
EP3124600B1 (en) Method for generating a cell condensate for self-organisation
Alsberg et al. Environmental cues to guide stem cell fate decision for tissue engineering applications
KR102254082B1 (en) Method for producing retinal pigment epithelial cell sheet
Köllmer et al. Stem cell-derived extracellular matrix enables survival and multilineage differentiation within superporous hydrogels
WO2008127256A1 (en) Control of cells and cell multipotentiality in three dimensional matrices
KR20140033008A (en) Method of producing retinal pigment epithelial cell sheet
Metallo et al. Engineering tissue from human embryonic stem cells
JP6097076B2 (en) Progeny of differentiated pluripotent stem cells that exclude excluded phenotypes
KR20160026840A (en) Use of microparticles and endothelial cells with decellularized organs and tissues
WO2012003465A2 (en) Scaffold-free three dimensional nerve fibroblast constructs
Ma et al. Preservation of human limbal epithelial progenitor cells on carbodiimide cross-linked amniotic membrane via integrin-linked kinase-mediated Wnt activation
JP2023055732A (en) Composition and method for bioengineered tissue
Jiang et al. Laminin-521 promotes rat bone marrow mesenchymal stem cell sheet formation on light-induced cell sheet technology
JP4724836B2 (en) Cell release method, cell release solution, cell culture method, cell culture solution, cell solution, cell solution preparation, cell fixing method and cell fixing solution
CN112538458A (en) Method for reprogramming cells
Hsu et al. Spheroid formation from neural stem cells on chitosan membranes
JP2012125207A (en) Scaffold for culturing corneal parenchymal cell
US20200109368A1 (en) Method for preparing differentiation-induced cells
JPWO2020067436A1 (en) Method for forming grafts of pluripotent stem cell-derived cells
JPWO2020067435A1 (en) Method for sheeting pluripotent stem cell-derived cells
JP2824081B2 (en) Cell culture method

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110315

R150 Certificate of patent or registration of utility model

Ref document number: 4724836

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350